-
公开(公告)号：US12115338B2
公开(公告)日：2024-10-15
申请号：US17655532
申请日：2022-03-18
申请人： Beta Bionics, Inc.
CPC分类号： A61M5/1407 , A61M5/142 , A61M5/162 , A61M5/1723 , A61M39/24 , A61M2205/8206 , A61M2205/8243
摘要： Certain embodiments provide multi-medicament infusion systems for preventing the cross-channeling of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The infusion pump can have an inductively chargeable battery assembly that can be charged by an inductive charging pad.
-
公开(公告)号：US20230405224A1
公开(公告)日：2023-12-21
申请号：US18296443
申请日：2023-04-06
申请人： Beta Bionics, Inc.
CPC分类号： A61M5/1723 , G16H20/17 , A61M2230/201 , A61M2205/502
摘要： A glucose level control system may be configured to determine a recommended medicament dose based at least in part on a subject's therapy data and/or user-specified medicament related inputs. The therapy data may include glucose level data and medicament delivery data. The user-specified medicament related inputs may include qualitative meal announcements. For example, the user can specify that the subject consumed a small, medium, or large meal. The glucose level control system may be configured to output an indication of the recommended medicament dose to a display. The glucose level control system may be configured to output a dose control signal to preconfigure a smart pen to deliver the recommended medicament dose. The glucose level control system may be configured to generate an alert if it determines, based at least in part on glucose level data and/or medicament delivery data associated with the subject, that trigger criteria have been satisfied.
-
公开(公告)号：US20230381413A1
公开(公告)日：2023-11-30
申请号：US18322678
申请日：2023-05-24
申请人： Beta Bionics, Inc.
CPC分类号： A61M5/1723 , G16H20/17 , A61B5/14532
摘要： A glucose level control system may be configured to adapt a time-segmented basal dose. The glucose level control system may determine the first basal dose based at least in part on a user-specified basal dose and/or total daily dose value. The first basal dose may also be based on a basal dose received from the memory of the glucose level control system or from a remote storage device. The first basal dose may be administered during a first time period. The glucose level control system may adapt the first basal dose to a second basal dose for a second therapy period. The glucose level control system may adapt the second basal dose based on a difference between a predicted and measured glucose level.
-
公开(公告)号：US11771821B2
公开(公告)日：2023-10-03
申请号：US17110497
申请日：2020-12-03
发明人： Edward R. Damiano , Rajendranath Selagamsetty , Firas H. El-Khatib , Bryan D. Knodel , Raymond A. Carr
CPC分类号： A61M5/1408 , A61J1/201 , A61J1/2065 , A61M5/1684 , A61J1/1406 , A61J1/1481 , A61J1/2037 , A61J1/2096 , A61J2200/70 , A61J2205/10 , A61J2205/60
摘要： Multi-medicament infusion systems prevent cross-channeling of medicaments. A system may include one or more of an infusion pump, medicament reservoirs, a multi-channel fluid conduit, and an infusion set. Medicament reservoirs and/or collars may be sized and shaped differently such that the medicament reservoirs can only be inserted into the system under selected configurations.
-
公开(公告)号：US11633535B2
公开(公告)日：2023-04-25
申请号：US17038949
申请日：2020-09-30
申请人： BETA BIONICS, Inc.
摘要： Certain embodiments provide multi-medicament or single medicament infusion systems for preventing the cross-channeling or improper delivery of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The medicament cartridges may be sized and shaped differently such that the medicament reservoirs can only be inserted into the pump under selected configurations.
-
公开(公告)号：US11594314B2
公开(公告)日：2023-02-28
申请号：US17653107
申请日：2022-03-01
申请人： Beta Bionics, Inc.
IPC分类号： G16H20/17 , A61M5/172 , A61M5/142 , H04W4/80 , G16H40/60 , G16H50/50 , G16H40/67 , G06F21/31 , G16H20/60 , G06F21/34 , G16H50/20 , G16H40/63 , A61B5/145 , A61B5/00
摘要： Blood glucose control systems are disclosed. A blood glucose control system can receive a glucose level signal from a glucose sensor operatively coupled to a subject. The system can decode encoded data of the glucose level signal to obtain the glucose level of the subject and the indication of the glucose trend. The system can automatically calculate the dose control signal using a control algorithm configured to calculate regular correction boluses of glucose control agent in response to at least the glucose level of the subject. The system can select a dose control signal encoding profile from a plurality of dose control signal encoding profiles and, based on the dose control signal encoding profile, encode the dose control signal such that the pump controller can read the dose control signal. The system can transmit an encoded dose control signal to the pump controller.
-
公开(公告)号：US20220288309A1
公开(公告)日：2022-09-15
申请号：US17579419
申请日：2022-01-19
申请人： Beta Bionics, Inc.
IPC分类号： A61M5/172 , G16H20/17 , G16H40/40 , G06F8/656 , H04W76/10 , A61M5/142 , G06F8/61 , H04L67/00 , G16H40/60 , G16H80/00 , A61M5/168 , G08B21/04 , G08B21/18 , G16H40/67 , G06F21/30 , G06F21/31 , G06F21/62 , G06F21/84 , G16H10/60 , G16H50/30 , G06F3/04883 , G06F8/65 , H04L9/40 , H04W76/14 , H04L9/08 , H04L9/30 , G06F3/04847
摘要： Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users.
-
公开(公告)号：US20220223251A1
公开(公告)日：2022-07-14
申请号：US17656345
申请日：2022-03-24
申请人： Beta Bionics, Inc.
摘要： Ambulatory medical devices, which includes ambulatory medicament pumps, and blood glucose control systems that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and devices can implement one or more features that improve the user experience, such as prompting and/or facilitating the user to order additional infusion sets, sensors, and/or other components to facilitate treatment.
-
公开(公告)号：US20220208370A1
公开(公告)日：2022-06-30
申请号：US17655122
申请日：2022-03-16
申请人： Beta Bionics, Inc.
摘要： Ambulatory medical devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and devices can transmit a request to modify blood glucose control therapy delivered to a subject. The request can be transmitted via a remote computing environment, the ambulatory medicament pump can include a medicament reservoir, a pump controller, a wireless data interface, and/or other elements. The device can receive an indication that the request to modify therapy is approved and, in response to the indication that the request to modify the blood glucose control therapy is approved, instruct the pump controller to modify the blood glucose control therapy delivered to the subject.
-
公开(公告)号：US20220193340A1
公开(公告)日：2022-06-23
申请号：US17685292
申请日：2022-03-02
申请人： Beta Bionics, Inc.
发明人： Himanshu Patel , Justin P. Brown
摘要： Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
-
-
-
-
-
-
-
-
-
搜索结果
128 条记录 (耗时 0.038 秒)
